Participant flow

Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1) · Source last updated 2026-05-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Patients receive erdafitinib 8 mg PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout study. Patients may also undergo blood sample collection and tumor biopsy throughout the trial.

   id

   FG000

   title

   Treatment (Erdafitinib)

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         17

      type

      Mutation Status Not Confirmed

   2. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Adverse Event

   3. reasons

      1. group Id

         FG000

         num Subjects

         5

      type

      Death

   4. reasons

      1. group Id

         FG000

         num Subjects

         8

      type

      Disease progression

   5. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Withdrawal by Subject

   6. reasons

      1. group Id

         FG000

         num Subjects

         3

      type

      Physician Decision

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         35

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         34

      type

      Eligible

   3. achievements

      1. group Id

         FG000

         num Subjects

         34

      type

      Started Protocol Therapy

   4. achievements

      1. group Id

         FG000

         num Subjects

         33

      type

      Eligible and Treated

   5. achievements

      1. group Id

         FG000

         num Subjects

         18

      type

      Mutation Status Confirmed

   6. achievements

      1. group Id

         FG000

         num Subjects

         18

      comment

      Primary efficacy analysis population

      type

      Eligible, Treated and Mutation Status Confirmed

   7. achievements

      1. group Id

         FG000

         num Subjects

         0

      comment

      Treatment continued until disease progression or intolerability

      type

      COMPLETED

   8. achievements

      1. group Id

         FG000

         num Subjects

         35

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

The FGFR amplification status was determined by assay performed in a NCI-MATCH approved laboratory for all patients in this arm. Mutation status was confirmed by central MATCH assay for 18 patients.

recruitment Details

The study was activated on June 20, 2018. Thirty-five patients were enrolled between August 20, 2018, and April 30, 2019.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice